Prelude Therapeutics (PRLD) Enterprise Value (2019 - 2026)
Prelude Therapeutics (PRLD) posted Enterprise Value of -$144.6 million for Q1 2026, down 40.1% sequentially from -$103.2 million in Q4 2025, and down 40.23% YoY from -$241.9 million in Q1 2025.
Prelude Therapeutics (PRLD) Enterprise Value (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Enterprise Value for 8 years, with the latest figure at -$144.6 million in Q1 2026.
- Quarterly Enterprise Value fell 40.23% year-over-year to -$144.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$144.6 million (down 40.23% YoY) and the FY2025 annual result came in at -$103.2 million, up 25.02% from the prior year.
- Enterprise Value slipped to -$144.6 million in Q1 2026 per PRLD's latest filing, from -$103.2 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$55.0 million in Q3 2025 and troughed at -$270.2 million in Q1 2022.
- A 5-year average of -$181.0 million and a median of -$183.9 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2025 and 2026: Enterprise Value soared 65.14% in 2025, then plunged 40.23% in 2026.
- Over 5 years, Enterprise Value stood at -$205.8 million in 2022, then slipped by 15.17% to -$237.0 million in 2023, then jumped by 41.91% to -$137.7 million in 2024, then grew by 25.02% to -$103.2 million in 2025, then slumped by 40.1% to -$144.6 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$144.6 million, -$103.2 million, and -$55.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | -280.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -280.63 Mn |
| Mar 31, 2026 | -144.60 Mn |
| Dec 31, 2025 | -103.21 Mn |
| Sep 30, 2025 | -54.96 Mn |
| Jun 30, 2025 | -124.76 Mn |
| Mar 31, 2025 | -103.12 Mn |
| Dec 31, 2024 | -137.66 Mn |
| Sep 30, 2024 | -157.67 Mn |
| Jun 30, 2024 | -183.89 Mn |
| Mar 31, 2024 | -205.97 Mn |
| Dec 31, 2023 | -236.98 Mn |
| Sep 30, 2023 | -234.55 Mn |
| Jun 30, 2023 | -259.03 Mn |
| Mar 31, 2023 | -176.30 Mn |
| Dec 31, 2022 | -205.77 Mn |
| Sep 30, 2022 | -228.09 Mn |
| Jun 30, 2022 | -250.35 Mn |
| Mar 31, 2022 | -270.23 Mn |
| Dec 31, 2021 | -295.28 Mn |
| Sep 30, 2021 | -320.87 Mn |